Welcome to Open Science
Contact Us
Home Books Journals Submission Open Science Join Us News Unsubscribe Page
Serum Lipid Profiles in Chronic Kidney Disease Patients on Haemodialysis at Parkview Renal Unit
Current Issue
Volume 6, 2018
Issue 3 (September)
Pages: 50-54   |   Vol. 6, No. 3, September 2018   |   Follow on         
Paper in PDF Downloads: 16   Since Aug. 9, 2018 Views: 164   Since Aug. 9, 2018
Authors
[1]
Sibusisiwe Sibanda, Department of Medical Laboratory Sciences, University of Zimbabwe, Harare, Zimbabwe.
[2]
Danai Tavonga Zhou, Department of Medical Laboratory Sciences, University of Zimbabwe, Harare, Zimbabwe.
Abstract
Chronic kidney disease is a condition where there is loss of kidney function over time. Sometimes acute kidney injury develops into chronic kidney disease. In such situations, renal replacement therapy may be prescribed which includes kidney transplant, peritoneal dialysis, hemodialysis and hemodiafiltration. Haemodialysis is a process that uses diffusion principles to remove metabolites from the blood using a dialyzer. Chronic kidney disease patients are known to be at risk for cardiovascular diseases and the lipid profile and cardiovascular indices may be used to assess this. This cross-sectional study was used to assess lipid dysfunction in 55 chronic kidney disease patients, on haemodialysis, attending Parkview Renal Unit in Harare, Zimbabwe. Total cholesterol (TC) levels of all patients were in the normal ranges as recommended by the National Cholesterol Education Program (NCEP) and The Kidney Dialysis Outcome Quality Initiative. Approximately 82% of the population had decreased high density lipoprotein (HDLc), 7% had elevated low density lipoprotein (LDLc), and 2% had a high LDLc/HDLc ratio while 4% had a high TC/HDLc ratio. Of the chronic kidney disease patients on haemodialysis at Parkview Renal Unit, at most 82% are at a risk of developing cardiovascular disease when determined using reduced HDLc levels as an index but risk is low when using CVD indeces.
Keywords
Chronic Kidney Disease, Haemodialysis, Lipid Profile, HDLc, LDLc, TC
Reference
[1]
Burtis, C. A and Bruns, D. E (2008): Tietz Fundamentals of Clinical Chemistry 6th edition, Missouri USA: Saunders Press.
[2]
Lewis, R (2012): Understanding Chronic Kidney Disease: A Guide For The Non Specialist, Florida USA: M and K Update Limited.
[3]
Workeneh, B. T (2013): Acute kidney failure- cardiovascular complications. Medscape. Article 243492.
[4]
Long, B, Koyfman, A, Lee, C. M, (2017): Emergency medicine evaluation and management of the end stage renal disease patient, The American Journal of Emergency Medicine; 35 (12), 1946–1955.
[5]
Levey, A. S, Echardt, K. U, Tsukamoto, Y, (2005): Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney International; 64 (6), 2089-2100.
[6]
Stevens, L. M, Lynm, C, Class, R. M, (2009): Kidney Failure, The Journal of the American Medical Association; 301 (6), 686-7.
[7]
Harmankaya, O, Akalin, N, Akay, H, Okuturlar, Y, Erturk, K, Kaptanogullari, H, Kocoglu, H, (2015): Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients, Clinics; 70 (9), 601-605.
[8]
World Health Organization, (2017): Cardiovascular diseases Fact sheet, Available @ http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
[9]
Prasad, M, Hermann, J, Gabriel, S. E, Weyand, C. M, Mulvagh, S, Mankad, R, Oh J. K, Matteson E. L, Lerman, A, (2015): Cardiorheumatology: cardiac involvement in systemic rheumatic disease, Nature Reviews Cardiology; 12, 168–176.
[10]
Rostand, S. G, (2000): Coronary Heart Disease in Chronic Renal Insufficiency, Journal of the American Society of Nephrology; 11, 1948- 1956.
[11]
Chowdary, R, Rohini, Reddy, P, (2015): Relationship between parathyroid hormone and serum creatinine levels in chronic kidney disease patients, J Med Sci Res; 3 (1): 17-21.
[12]
Tsimihodimos, V, Mitrogianni, Z, Elisaf, M, (2011): Dislipidaemia associated with Chronic Kidney Disease, The Open Cardiovascular Medicine Journal; 5, 41-48.
[13]
Opasich C, Cazzola M, Scelsi L, De Feo S (2005): Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure, European Heart Journal; 26 (21), 2232-2237.
[14]
Okonko, D. O, Anker, S. D, (2004): Anemia in chronic heart failure: pathogenetic mechanisms. Journal of Cardiac Failure; 10 (1), S5-S9.
[15]
Altaf, A, Halim, A, Khan, D. A, Khalid, M, Zuhra, F-T, Saif, I, (2007): Assessment of Lipid Dysfunction in Patients on Maintenance Haemodialysis, J Ayub Med Coll Abbottabad; 19 (4) 32-36.
[16]
Chijioke, N. N, Bartimaeus E. A. S, Okeke C. U, (2012): Lipid Profile in Chronic renal failure Patients on Dialysis. European Journal of Cardiovascular Medicine, 2, 106-109.
[17]
Hamida, F. B, Smaoui, W, Helal, I (2010): Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi Journal of Kidney Diseases and Transplantation, 21, 59-62.
[18]
Visconti, L, Benvenga, S, Lacquaniti, A. A, Cernaro, V, Bruzzese, A, Conti, G, Buemi, M, Santoro, D (2016): Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. Journal of Clinical & Translational Endocrinology; 6: 8-14.
[19]
National Kidney Foundation (2003): Kidney Dialysis Outcome Quality Initiative clinical practice guidelines for managing dyslipidemias in chronic kidney disease. American Journal of Kidney Disease; 41, S1-S92.
[20]
Mikolasevic I, Žutelija M, Mavrinac V, Orlic L (2017): Dyslipidemia in patients with chronic kidney disease: etiology and management. International Journal of Nephrology and Renovascular Disease; 10: 35-45.
[21]
Prichard, S. S (2003): Impact of dyslipidemia in end stage renal disease. Journal of the American Society of Nephrology; 14, S315- S320.
[22]
Baria, D, Joshi, V, Shah, T, Gandah, K, Modi, N (2013): Impact of Hemodialysis on Lipid Profile among Chronic Renal Failure Patients. International Journal of Scientific and Research Publications, 3, 1-3.
[23]
Mascarenhas-Melo, F, Sereno, J, Teixeira-Lemos, E, Ribeiro, S, Rocha-Pereira, P, Cotterill, E, Teixeira, F, Reis, F (2013): Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations, Disease Markers; 35 (2) 85-96.
[24]
Mindray Biomedical Company Limited: Biochemistry handbook for Mindray, Shenzhou city, Guangdong province, China, 38-47.
[25]
Fragos, A, Mendes, F, Silva A. P, Neves, P. L, (2015): Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease, Journal of Diabetes and its Complications; 29 (8), 1098-1104.
[26]
Oksala, N, Seppälä, I, Hernesniemi, J, Lyytikäinen, L-P, Kähönen, M, Kari-Matti Mäkelä, K-M, (2013): Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study, Annals of Medicine; 45 (2) 141-148.
[27]
Dinov, I. D, Cristom N, Sanchez J (2008): Central Limit Theorem: New SOCR Applet and Demonstration Activity. Journal of \Statistic Education, 16 (2), 1-7.
Open Science Scholarly Journals
Open Science is a peer-reviewed platform, the journals of which cover a wide range of academic disciplines and serve the world's research and scholarly communities. Upon acceptance, Open Science Journals will be immediately and permanently free for everyone to read and download.
CONTACT US
Office Address:
228 Park Ave., S#45956, New York, NY 10003
Phone: +(001)(347)535 0661
E-mail:
LET'S GET IN TOUCH
Name
E-mail
Subject
Message
SEND MASSAGE
Copyright © 2013-2017, Open Science Publishers - All Rights Reserved